Loxo Oncology, Inc
LOXO
LOXO was delisted on the 14th of February, 2019.
232 hedge funds and large institutions have $4.15B invested in Loxo Oncology, Inc in 2018 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 77 increasing their positions, 85 reducing their positions, and 31 closing their positions.
78% more call options, than puts
Call options by funds: $21.9M | Put options by funds: $12.3M
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
16% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 31
2% more funds holding
Funds holding: 228 → 232 (+4)
9% less repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 85
19% less capital invested
Capital invested by funds: $5.13B → $4.15B (-$971M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$72.3M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$49.3M |
| 3 |
Millennium Management
New York
|
+$32.6M |
| 4 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$20.2M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$18.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$56.4M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$55M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$30.9M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
-$23.5M |
| 5 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
-$22.4M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RFA
251
Reilly Financial Advisors
La Mesa,
California
| – | -$68K | -400 | Closed |
|
|
MYIA
252
Mount Yale Investment Advisors
Denver,
Colorado
| – | -$43K | -243 | Closed |
|
253
Group One Trading
Chicago,
Illinois
| – | -$35K | -202 | Closed |
|
|
KF
254
Krilogy Financial
St. Louis,
Missouri
| – | -$26K | -150 | Closed |
|
|
SFM
255
Signet Financial Management
Parsippany,
New Jersey
| – | -$19K | -112 | Closed |
|
|
FANJ
256
Financial Architects (New Jersey)
Marlton,
New Jersey
| – | -$17K | -100 | Closed |
|
|
TRCT
257
Tower Research Capital (TRC)
New York
| – | -$15K | -85 | Closed |
|
|
TC
258
Trilogy Capital
Irvine,
California
| – | -$7K | -40 | Closed |
|
259
Fifth Third Bancorp
Cincinnati,
Ohio
| – | -$5K | -29 | Closed |
|
|
APP
260
Avantax Planning Partners
Dubuque,
Iowa
| – | -$5K | -28 | Closed |
|
261
Parallax Volatility Advisers
San Francisco,
California
| – | -$3K | -17 | Closed |
|
|
EFSCE
262
Enterprise Financial Services Corp (EFSC)
Clayton,
Missouri
| – | -$2K | -11 | Closed |
|
|
WC
263
Whitney & Co
Rochester,
New York
| – | -$2K | -9 | Closed |
|
LOXO Hedge Fund Activity: Q4 2018 in Review
232 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q4 2018, worth a combined $4.15B — down 19% from $5.13B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new LOXO positions and 31 closed out — a net gain of 5 holders — while 77 added to existing stakes and 85 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $72.3M. The largest seller was OrbiMed, exiting entirely with an estimated $56.4M sold.
- 232 institutional investors held Loxo Oncology, Inc (LOXO) as of Q4 2018, up from 228 in Q3 2018.
- Funds reported $4.15B of Loxo Oncology, Inc stock for Q4 2018, down 19% quarter-over-quarter.
- 36 funds opened new Loxo Oncology, Inc positions in Q4 2018 and 31 closed out, a net change of +5 holders.
- The largest Loxo Oncology, Inc buyer in Q4 2018 was Point72 Asset Management, an estimated $72.3M added.
- The largest Loxo Oncology, Inc seller in Q4 2018 was OrbiMed, an estimated $56.4M sold.
Based on aggregated 13F filings for Q4 2018.